EPA’s Integrated Risk Information System (IRIS) program is developing assessments for five PFAS: perfluorobutanoic acid [PFBA], perfluorohexanoic acid [PFHxA], perfluorohexane sulfonate [PFHxS], perfluorononanoic acid [PFNA], perfluorodecanoic acid [PFDA], and their associated salts. On February 2, EPA released the draft IRIS assessment for PFHxA.
The IRIS assessment followed a systemic review protocol that outlines the related scoping and problem formulation efforts, including a summary of other federal and state assessments of PFHxA. The protocol also lays out the systematic review and dose-response methods used to conduct the review.
The review found that PFHxA exposure is likely to cause hepatic, developmental, and hematopoietic effects in humans. In addition, the review reported that current evidence suggests that PFHxA exposure might cause endocrine effects in humans.